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4) 5a-Reductase is an NADPH-dependent enzyme responsible for the conversion of testosterone to DHT. As a consequence, a 5a-reductase inhibitor is expected to provide a potential treatment for BPH. Several 5a-reductase inhibitors have been reported which might provide a novel therapeutic treatment for androgen-related disorders, 5, 6) including both steroidal inhibitors, finasteride 5a) and epristeride, 5b) and a nonsteroidal inhibitor, ONO-3805 6a) (Fig.  1) . Following the discovery of these inhibitors, the existence of two different 5a-reductase isozymes, called type 1 and type 2 5a-reductase, have been reported in humans and rats. [7] [8] [9] The type 1 enzyme is normal in men with congenital 5a-reductase deficiency and is expressed in skin tissue throughout the body that has an optimal pH of between 6 and 9. The type 2 enzyme is defective in men with congenital 5a-reductase deficiency and is the dominant form of the enzyme in genital tissue, including prostate that has an optimal pH of about 5.5. However, the physiological role of these isozymes has yet to be fully elucidated. Steroidal inhibitors have demonstrated clinical efficacy for the treatment of BPH; however, there is a possibility of adverse effects due to their steroidal structures. 10) On the other hand, nonsteroidal inhibitors have not shown clinical efficacy for the treatment of BPH. Finasteride showed strong inhibitory activity (IC 50 ϭ 4.1 nM) 11) for human prostatic 5a-reductase, whereas ONO-3805 showed only moderate activity (IC 50 ϭ538 nM) 11) which might not be sufficient to show clinical efficacy. We considered that a more potent nonsteroidal inhibitor of human prostatic 5a-reductase than ONO-3805 could show clinical efficacy for the treatment of BPH and have reduced potential for side effects compared to steroidal inhibitors. To develop potent nonsteroidal 5a-reductase inhibitors, we began a chemical file screening program and found that the benzoic acid derivative 1 showed moderate inhibitory activity for 5a-reductase in HS27 human foreskin fibroblast cells 8) with an IC 50 value of 317 nM. In order to increase the inhibitory activity against human prostatic 5a-reductase, we began modifications of the benzoic acid derivative 1. This report describes the results of structure-activity relationships of the benzoic acid derivatives.
Chemistry Benzoic acids (2a-2i, 2l-2p) were prepared by alkylation of phenol derivatives (3, 4) and subsequent oxidation of the intermediate aldehydes or hydrolysis of the intermediate esters and nitrile as shown in Chart 1. NArylation of 4-aminobiphenyl with 4-fluorobenzonitrile in the presence of NaH followed by hydrolysis with NaOH gave 2j (Chart 2). Compound 2k was prepared as shown in Chart 3. Compound 10, prepared by addition of biphenyl-4-yllithium to 4-diethoxymethylbenzaldehyde, was hydrolyzed with HCl, and the resulting aldehyde was converted to the carboxylic acid 11 by oxidation with Ag 2 O. The dehydroxylation of 11 was performed using Me 2 SiCl 2 and NaI to give 2k. 12) 3-Nitrobenzoic acid derivative 2q and 3-aminobenzoic acid derivative 2r were prepared as shown in Chart 4. Compound 13 was hydrolyzed with NaOH to give the carboxylic acid 2q. Compound 2r was obtained by the reduction of 13 in the presence of Pd-C and subsequent hydrolysis with NaOH. Compounds 2s, 2t and 2u were obtained by Ullmann condensations and subsequent conversion into carboxylic acids, as shown in Chart 5.
Results and Discussion
The inhibitory activities of the benzoic acid derivatives were evaluated on the basis of the ability to inhibit 5a-reductase in HS27 human foreskin fibroblast cells and human prostate at pH 5.5 which is optimal for the activity of the type 2 enzyme. The results are described in Tables 1-4. We found the benzoic acid derivative 1, which showed moderate inhibitory activity for 5a-reductase in HS27 by a chemical file screening program. Initially, the effects of the length of the alkylene moiety and substituents at the 4-position of the benzene ring B in compound 1 were investigated as described in Table 1 . Elongation of the alkylene moiety (2a, 2b) retained potency, while the phenoxy benzoic acid derivative 2c which has no alkylene moiety resulted in a slight increase in the activity to 5a-reductase in HS27 with an IC 50 value of 105 nM. Furthermore, replacement of the isopropyl group in compound 2c with a phenyl group (2d) showed 40-fold greater inhibitory activity, with an IC 50 value of 7.8 nM. These results suggest that an aryloxy group is more favorable than an alkoxy group as the substituent of benzene ring A for high potency. Since compound 2d showed potent inhibitory activity for 5a-reductase in human prostate with an IC 50 value of 1.1 nM, we next focused our efforts on the biphenyl derivative 2d and modification of this compound was carried out in order to increase the inhibitory activity against human prostatic 5a-reductase.
Replacement of the phenyl group in compound 2d with a benzyl group (2e), phenoxy group (2f), or (E)-styryl group (2g) resulted in a decrease in activity compared to compound 2d, suggesting a phenyl group to be beneficial at this position.
Concerning the position of the phenyl group (benzene ring C) of compound 2d, the 3-phenyl derivative 2h resulted in a slight loss of activity with an IC 50 value of 6.4 nM, while the 2-phenyl derivative 2i resulted in a dramatic loss of activity, as described in Table 2 . These results suggest that the distance between benzene ring C and the carboxyl group is important for potent inhibitory activity. In order to investigate the influence of distance, optimized structures for phenoxybenzoic acid derivatives 2d-2i were calculated by a system-atic search and minimization using the molecular modeling program Sybyl, version 6.3, and the distances between the carbon of the carboxyl group and centroid of benzene ring C were calculated from their optimized structures. The calculated data and the optimized structures of compounds 2d-2i are shown in Table 3 and Fig. 2 , respectively. Among them, the most potent compound 2d is a linear compound, and the centroid of benzene ring C is positioned at a distance of around 10.5 Å from the carboxyl group through the benzene ring juncture. The corresponding distances of compounds 2e and 2g which showed 10 times less potent inhibitory activities than compound 2d, were around 8.8 and 12.5 Å, respectively. On the other hand, compound 2i is a non-linear compound, and the position of the benzene ring C is probably too close to the carboxyl group (C-centroid distanceϭ8.062 Å) to show potent inhibitory activity. These data led us to speculate that the favorable distance between the carboxyl group and the centroid of benzene ring C was estimated to be in the 9-11 Å range and that there is a hydrophobic pocket interacting with benzene ring C in the enzyme.
Next, modification of the ether linker of compound 2d was investigated. Substitution of the ether linker of compound 2d with amine (2j) or methylene (2k) reduced inhibitory activities, with IC 50 values of 25 and 10 nM, respectively, demonstrating the ether linker to be beneficial at this position.
Finally, the effects of substituents on the benzene rings A and B were investigated. Introduction of a chloro group at the 2-position of benzene ring B (2l) or benzene ring A (2m) resulted in a slight loss of potency, while introduction of a chloro group at the 3-position of benzene ring A (2n) showed strong potency, with an IC 50 value of 0.87 nM. Concerning substituents at the 3-position of benzene ring A, replacement with a fluoro (2o) or methoxy (2s) showed high potency with IC 50 values of below 1 nM. Furthermore, the 3-nitrobenzoic acid derivative 2q retained potency, while the 3-aminobenzoic acid derivative 2r showed reduced potency and the isophthalic acid derivative 2p resulted in a dramatic loss of activity. These findings demonstrated that the presence of a hydrophobic substituent at the 3-position of benzene ring A is favorable for potent inhibitory activity. Replacement of the methoxy group in compound 2s with isopropoxy (2t) or phenoxy (2u) resulted in decreased inhibitory activity compared to compound 2s, indicating that bulky substituents such as isopropoxy or phenoxy groups are unfavorable at this position.
Compounds 2n, 2o and 2s, which showed potent inhibitory activity for human prostatic 5a-reductase, were evaluated for their rat prostatic 5a-reductase inhibitory activities. The results are summarized in Table 4 . Finasteride and (Ϯ)-ONO-3805 exhibited inhibitory activities with IC 50 values of 13 and 2.6 nM against the rat prostatic enzyme, respectively. The benzoic acid derivatives 2n, 2o and 2s showed no measurable inhibition at 1 mM, suggesting these benzoic acid derivatives to be selective human prostatic 5a-reductase inhibitors. Possibly the low sequence homology between the human and rat enzymes is one reason.
7)

Conclusions
In order to develop more potent nonsteroidal inhibitors of human prostatic 5a-reductase than ONO-3805, we selected the benzoic acid derivative 1 as a lead compound and prepared mainly phenoxy benzoic acid derivatives. Consequently, we have identified a new series of biphenyl-4-yloxy benzoic acid derivatives as potent human prostatic 5a-reduc- tase inhibitors. In particular, compounds 2n (YM-31758), 2o and 2s showed more potent inhibitory activity than finasteride. The favorable distance between the carbon of the carboxyl group and the centroid of benzene ring C was revealed to be in the 9-11 Å range by molecular modeling analysis.
Further efforts to discover novel nonsteroidal inhibitors possessing more potent inhibitory activity for the human prostatic 5a-reductase are ongoing.
Experimental
Melting points were taken on a Yanaco MP-3 melting point apparatus and are uncorrected.
1 H-nuclear magnetic resonance ( 1 H-NMR) spectra were recorded on a JEOL FX-90, JNM-LA 300, JNM-LA 400, JNM-GX 400 or JNM-GX 500 spectrometer with tetramethylsilane as an internal standard. Mass (MS) spectra were recorded on a Hitachi M-80 (electron impact (EI)) or JEOL JMS-DX300 (FAB) mass spectrometer. Elemental analysis was performed with a Yanaco MT-5. Column chromatography was carried out on silica gel (Wakogel C-200). Unless otherwise noted, all reagents and solvents obtained from commercial suppliers were used without further purification. In general, the organic extract was dried over anhydrous Na 2 SO 4 or MgSO 4 , and the organic solvent was evaporated under reduced pressure. All non-aqueous reactions were performed in dry glassware under an atmosphere of dry Ar. The three-dimensional structures of the molecules were constructed using the molecular modeling program Sybyl (version 6.3) on an Indigo Elan workstation (Silicon Graphics Inc., Mountain View, CA). Each structure was energy-minimized using the Tripos force field with the default convergence criteria. 4-(5-Phenylpentyloxy)benzoic Acid (2a) A mixture of 3 (300 mg, 1.97 mmol), 5-bromo-1-phenylpentane (500 mg, 2.20 mmol), KI (0.06 mmol, 10 mg) and K 2 CO 3 (410 mg, 2.97 mmol) in N,N-dimethylformamide (DMF) (10 ml) was stirred at 100°C for 8 h. After dilution with AcOEt, the organic layer was washed with water and brine, dried and concentrated. The residue was recrystallized from EtOH to give methyl 4-(5-phenylpentyloxy)benzoate (280 mg, 47%). This intermediate (260 mg, 0.87 mmol) was dissolved in 4 ml of EtOH-dioxane (3 : 1), then 5 N NaOH aqueous solution (4.0 ml) was added, and the mixture was heated at 40°C for 30 min. The reaction mixture was acidified with 3 N HCl aqueous solution and extracted with AcOEt. The extract was washed with brine, dried and concentrated, and the residue was recrystallized from EtOH to give 2a (100 mg, 40%): mp 150-151°C; .0 mmol) in dimethyl sulfoxide (DMSO) (20 ml) was stirred at 100°C for 6.5 h. After dilution with AcOEt, the organic layer was washed with water and brine, dried and concentrated. The residue was recrystallized from EtOH to give 4-(biphenyl-4-yloxy)benzaldehyde (1.93 g, 70%). This intermediate (550 mg, 2.00 mmol) was dissolved in 22 ml of EtOH-water (1 : 1), then silver nitrate (710 mg, 4.18 mmol) and NaOH (320 mg, 8.00 mmol) were added, and the mixture was refluxed for 1 h. The precipitate was removed by filtration and the filtrate was concentrated. The residue was acidified with 1 N HCl aqueous solution and extracted with AcOEt. The extract was washed with brine, dried and concentrated, and the residue was recrystallized from EtOH to give 2d (510 mg, 88%): mp 237-239°C; 1 H-NMR (DMSO-d 6 
4-(Biphenyl-4-yloxy)isophthalic Acid (2p)
A mixture of 6 (4.00 g, 13.3 mmol), biphenyl-4-ol (2.26 g, 13.3 mmol) and K 2 CO 3 (2.76 g, 20.0 mmol) in DMSO (13 ml) was stirred at 100°C for 4 d. After dilution with AcOEt, the organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ19 : 1) to give diethyl 4-(biphenyl-4-yloxy)isophthalate (1.79 g, 39%). This intermediate (390 mg, 1.00 mmol) was dissolved in 4.5 ml of EtOH-dioxane (1 : 2), then 5 N NaOH aqueous solution (1.5 ml) was added, and the mixture was heated at 50°C for 2 d and then concentrated. The residue was acidified with 3 N HCl aqueous solution and extracted with AcOEt. The extract was washed with brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; EtOH : AcOEtϭ2 : 3) and recrystallized from EtOH to give 2p ( -4-ylamino)benzonitrile (8) To a solution of 7 (1.69 g,  10 .0 mmol) in DMSO (7 ml), 60% NaH (440 mg, 11.0 mmol) was added, Vol. 47, No. 8 (Biphenyl-4-yl)(4-diethoxymethylphenyl)methanol (10) To a solution of 9 (1.40 g, 6.00 mmol) in tetrahydrofuran (THF) (30 ml), BuLi (1.6 M in hexane; 5.4 ml, 8.6 mmol) was added dropwise at Ϫ70°C, and the mixture stirred at this temperature for 15 min, and a solution of 4-diethoxymethylbenzaldehyde (1.25 g, 6.00 mmol) in THF (5 ml) was added dropwise. Stirring was continued for 1.5 h at Ϫ70°C and the reaction was then quenched with ice-water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent; hexane : AcOEtϭ10 : 1) to give 10 (1.79 g, 82%): 
4-(Biphenyl
4-[(Biphenyl-4-yl)(hydroxy)methyl]benzoic Acid (11)
To a solution of 10 (1.79 g, 4.90 mmol) in THF (50 ml), 1 N HCl aqueous solution (10 ml) was added, and the mixture was stirred at room temperature for 30 min and then concentrated. After dilution with AcOEt and water, the organic layer was washed with water and brine, dried and concentrated to give 4-[(biphenyl-4-yl)(hydroxy)methyl]benzaldehyde (1.32 g). This crude material (1.32 g, 4.60 mmol) was dissolved in 60 ml of EtOH-water (1 : 1), silver nitrate (2.33 g, 13.7 mmol) and NaOH (1.10 g, 27.5 mmol) were added, and the mixture was refluxed for 5 h. The precipitate was removed by filtration and the filtrate was concentrated. The residue was acidified with 1 N HCl aqueous solution and extracted with AcOEt. The extract was washed with brine, dried and concentrated, and the residue was recrystallized from 2-propanol to give 11 (1.08 g, 78%): To a solution of 13 (1.78 g, 5.10 mmol) in EtOH (70 ml), 10% Pd-C (100 mg) was added. The flask was then placed under hydrogen atmosphere and stirred at room temperature for 20 h. The reaction mixture was filtered to remove the catalyst, and the filtrate was concentrated to give methyl 3-amino-4-(biphenyl-4-yloxy)benzoate (1.62 g). This crude material (190 mg) was dissolved in 1.5 ml of MeOH-dioxane (1 : 2), then 1 N NaOH aqueous solution was added, and the mixture was stirred at 50°C for 18 h. After the reaction mixture was concentrated, the residue was taken up in water (15 ml), and the pH was adjusted to 7 by the addition of 1 N HCl aqueous solution. The mixture was washed with AcOEt, and 12 N HCl (3 ml) aqueous solution was added. The resulting crystals were collected by filtration to give 2r ( 3 (1.0 M in CH 2 Cl 2 ; 11.6 ml, 11.6 mmol) was added dropwise at Ϫ78°C, and the mixture was stirred at 0°C for 3 h. The reaction was quenched with ice-water and extracted with AcOEt. The organic layer was washed with water and brine, dried and concentrated. The residue was recrystallized from EtOH-hexane to give 16 (1.60 g, 83%): 
. Authentic Materials The 5a-reductase inhibitors finasteride 5a) and (Ϯ)-ONO-3805 6a) were synthesized in our company according to the methods described in the literature.
Biological Methods. Preparation of 5a a-Reductase from HS27, Rat Prostate and Human Prostate Human genital skin fibroblast cell line HS27 (CRL1634) was obtained from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium containing 10% heatinactivated fetal bovine serum, 100 unit/ml penicillin and 100 mg/ml streptomycin. The cell monolayer was released from the culture flask using 0.25% trypsin and 0.02% EDTA. The cells were washed 3 times with saline and collected by centrifugation. The cell pellet was suspended in 10 mM TrisHCl buffer (pH 7.0) and homogenized with a Teflon-glass homogenizer. The homogenate was sonicated for 30 sϫ3 times and centrifuged at 1000 g for 5 min. The supernatant was stored at Ϫ80°C until use.
Male Wistar rats 8-12 weeks of age (Charles River Japan Inc., Atsugi, Japan) were sacrificed and the ventral prostates were removed. The prostatic tissues were rinsed with ice-cold saline and minced with scissors. Unless specified, all the following procedures were carried out at 4°C. The minced tissues were homogenized with a Polytron homogenizer (Kinematica GMBH, Lucerne, Switzerland) in 3 tissue volumes of 20 mM sodium phosphate buffer pH 7.0 containing 0.25 M sucrose and 0.1 mM dithiothreitol (DTT). The homogenate was centrifuged at 10000 g for 10 min, and the resulting supernatant was centrifuged again at 140000 g for 60 min. The pellets were resuspended in 40 mM sodium phosphate buffer at pH 6.5. The suspension was stored at Ϫ80°C until use.
Human prostatic tissues from BPH patients who had received transurethral prostatectomy were kindly provided by Dr. T. Tahara at Yamato Hospital, Tokyo, Japan, and stored at Ϫ80°C until preparation of the enzyme fractions. The frozen prostatic tissues were minced with scissors and homogenized with a Polytron homogenizer in 3 tissue volumes of 10 mM Tris-HCl buffer pH 7.0 containing 0.33 M sucrose, 1 mM DTT and 1 mM NADPH. The homogenate was centrifuged at 1000 g for 5 min. The supernatant was centrifuged at 11000 g for 20 min, and the resulting supernatant was centrifuged again at 140000 g for 60 min. The resulting pellet was resuspended in 10 mM Tris-HCl buffer pH 7.0 and stored at Ϫ80°C until use.
5a a-Reductase Assay in Vitro 5a-reductase activities were assayed according to the method described by Liang et al. 13) with a minor modification. Briefly, the reaction solutions contained in a final volume of 0.5 ml: 1 mM [4-14 C] testosterone, 1 mM DTT, 50 mM NADPH, 50 mM buffer (Tris-HCl pH 6.5, for the rat prostate enzyme; Tris-citrate pH 5.0, for HS27 and the human prostate enzyme) and the enzyme fractions. To identify the inhibitory effect of the drugs, various concentrations of test compounds were added in 5 ml DMSO (final conc. 1%). The reaction solutions in duplicate were incubated at 37°C for 60 min, and the reaction was terminated by addition of 2.0 ml cold AcOEt containing 10 mg testosterone, 5a-DHT, 4-androstene-3,17-dione, 5a-androstan-3a-17b-diol and 5a-androstan-3,17-dione as the standards. The organic phase was separated by centrifugation, evaporated under N 2 gas and resuspended with 40 ml AcOEt. 20 ml of AcOEt was spotted on a TLC plate and separated twice by AcOEt/cyclohexane (1 : 1) as the developing solvent. The steroid standards were located by UV (254 nm) and by spraying with a 1% CeSO 4 -10% H 2 SO 4 solution, followed by heating. The regions containing 5a-reduced metabolites (5a-DHT, 5a-androstan3a-17b-diol and 5a-androstan-3,17-dione) were cut from the TLC plate and soaked in 5 ml of Aquasol-2 and the radioactivity was counted by a scintillation counter. The IC 50 values for 5a-reductase activity were obtained from the linear line drawn by the least-squares fitting method. 14) 
